

2024 Raleigh Campus Antibiogram Inpatient

GRAM POSITIVE								
Antibiogram 2024 Raleigh Campus Inpatient	*Anaerobic coverage	Enterococcus faecalis	Enterococcus faecium	Staphylococcus epidermidis	Staphylococcus hominis	Staph aureus (MSSA)	Staph aureus (MRSA)	Streptococcus pyogenes (Invasive)
Location		INPATIENTS						
# of isolates analyzed		449	51	196	34	586	444	32
		% Susceptible						
Ampicillin	*	100%	24%					100%
Ceftaroline						100%	100%	
Clindamycin	*			53%	59%	75%	72%	81%
Daptomycin		89%				100%	100%	
Erythromycin Base, Enteric	*			33%	18%	64%	14%	81%
Gentamicin Synergy (high level)		85%	82%					
Levofloxacin		85%	27%					97%
Linezolid		98%	92%	100%	100%	100%	100%	100%
Nitrofurantoin		99%	18%	99%	100%	100%	100%	
Oxacillin				41%	44%	100%	0%	
Penicillin G	*	100%	15%	0%	0%	0%	0%	100%
Streptomycin Synergy (high level)		93%	62%					
Tetracycline/Doxycycline	*			84%	68%	94%	78%	72%
Trimethoprim-sulfa				61%	71%	96%	77%	
Vancomycin		97%	47%	100%	100%	100%	100%	100%

This antibiogram has been prepared from SCC SOFT LIS.
 This antibiogram contains organisms isolated in 2023.
 Only the first isolate per patient is included in this data.
 * Denotes activity against anaerobes. Anaerobes are not tested for susceptibility profiles at WakeMed.

21 % of Inpatient MSSA are Clindmycin Inducible Resistant
 5% of Inpatient MRSA are Clindamycin Inducible Resistant

**Antibiograms are published annually for WakeMed Raleigh, WakeMed Cary and WakeMed North
 by the Microbiology Lab and the Antimicrobial Stewardship Program. 919-350-8075**

**WakeMed Health and Hospitals
 Raleigh, NC**